Cullinan Therapeutics, Inc. Common Stock

CGEMNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
13.51 USD
↘ 0.92 (6.38%)AT CLOSE (11:59 AM EDT)
13.54
↗ 0.03 (0.25%)
POST MARKET (AS OF 07:54 PM EDT)
Post Market
AS OF 07:54 PM EDT
13.54
↗ 0.03 (0.25%)
🔴Market: CLOSED
Open?$14.36
High?$14.47
Low?$13.47
Prev. Close?$14.43
Volume?753.8K
Avg. Volume?994.4K
VWAP?$13.90
Rel. Volume?0.76x
Bid / Ask
Bid?$11.69 × 100
Ask?$15.49 × 100
Spread?$3.80
Midpoint?$13.59
Valuation & Ratios
Market Cap?830.3M
Shares Out?61.5M
Float?47.0M
Float %?79.6%
P/E Ratio?N/A
P/B Ratio?2.27
EPS?-$3.18
Dividend?0.00%
Ex-Dividend?N/A

Cullinan Therapeutics, Inc. Common Stock (CGEM) is currently trading at $13.51. The technical outlook is "Sell" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
109
Market Cap
830.3M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.cullinantherapeutics.com
Listed
2021-01-08
Address
ONE MAIN STREET
CAMBRIDGE, MA 02142
Phone: 617-410-4650
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
45
Piotroski F-Score?0/9Weak
Altman Z-Score?10.32Safe
Confidence?45%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?18.45%High
Short Interest?8.7M
Days to Cover?8.2
Free Float47.0M
Avg Daily Volume1.1M
Settlement Date2026-05-15
Financial Health
Current Ratio?10.28Strong
Quick Ratio?10.28Strong
Cash Ratio?2.14Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
69
2.27CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.2CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-53.3%WEAK▾
ROA?
S&P
3
-48.4%WEAK▾
Cash Flow & Enterprise
FCF?$-178689000
Enterprise Value?$755.2M
Fundamentals ratios updated end of day
MarketsMoversWatchlist